Erudio Healtherudio.com
Sponsor
Gruppo Oncologico del Nord-Ovest trials: what clinicians said in public
An HCP commentary report on 1 clinical trial sponsored by Gruppo Oncologico del Nord-Ovest: BRICKET. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 3 more trials with public commentary and no report yet.
Listed by lead sponsor as registered on ClinicalTrials.gov (Gruppo Oncologico del Nord-Ovest). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| BRICKET NCT06578559 · Gruppo Oncologico del Nord-Ovest | BRAF V600E-mutated metastatic colorectal cancer | Phase 2 | 21 | 12 | Focused | Oct 28, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| AtezoTRIBE NCT03721653 · Gruppo Oncologico del Nord-Ovest DeepView → | first-line unresectable metastatic colorectal cancer | Phase 2 | Deep | View | |||
| TRIBE2 NCT02339116 · Gruppo Oncologico del Nord-Ovest DeepView → | first-line unresectable metastatic colorectal cancer | Phase 3 | Deep | View | |||
| PARERE NCT04787341 · Gruppo Oncologico del Nord-Ovest DeepView → | RAS and BRAF wild-type chemorefractory metastatic colorectal cancer | Phase 2 | Deep | View | |||